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Somatic calreticulin mutations in patients with
Budd-Chiari syndrome and portal vein thrombosis
We studied the role of the recently identified CALR
mutations in 141 patients with Budd-Chiari Syndrome
(BCS) or portal vein thrombosis (PVT) in a large multina-
tional cohort. A CALR mutation was present in one of the
141 patients (0.7%). This patient was previously diagnosed
with primary myelofibrosis. This results in CALR positivity
in one out of 44 (2.3%) patients with myeloproliferative
neoplasm (MPN), and in one of 11 (9.1%) JAK2V617F neg-
ative patients diagnosed with MPN. We suggest that analy-
sis of CALRmutations should be performed in JAK2V617F
negative BCS and PVT patients. 
BCS and non-malignant, non-cirrhotic PVT are rare vas-
cular liver diseases. The etiology of these diseases encom-
passes both inherited and acquired risk factors, of which
MPN are the most common with a prevalence ranging
between 20%-50%.1-3  Detecting presence of MPN in
patients with BCS and PVT is important, given the prog-
nostic and potential therapeutic implications regarding
anticoagulant therapy.4,5 However, diagnosing MPN in
patients with BCS and PVT is often difficult as portal hyper-
tension caused by the obstruction of the hepatic veins
and/or portal vein can explain splenomegaly, and decreases
peripheral blood cell counts through hypersplenism.6 The
discovery of the JAK2V617F mutation has greatly
improved the ability to non-invasively detect MPNs in
patients with BCS and PVT.7-9 However, in the absence of
the JAK2V617F mutation, diagnosing MPN can still be
challenging and a bone marrow biopsy remains required in
most patients and may still be inconclusive.4,10 Recently,
exome sequencing resulted in the detection of mutations in
CALR in patients with essential thrombocythemia (ET) or
primary myelofibrosis (PMF) lacking JAK2V617F and MPL
mutations. CALR mutations were present in 67%-88% of
these patients.11,12 Identification of CALR mutations in
patients with BCS and PVT without the characteristic
blood counts could improve the ability to diagnose ET and
PMF. The aim of our study was to determine the prevalence
and role of CALRmutations in patients with BCS and non-
malignant, non-cirrhotic PVT.
In this case-control study, patients and controls were
recruited from the European Network for Vascular Disease
of the Liver (EN-Vie) study cohort. This study cohort has
been described in detail elsewhere.2,3 For this study, consec-
utive, incident cases of BCS and non-malignant, non-cir-
rhotic PVT were enrolled between 2003 and 2005 and
prospectively followed in nine European countries. In addi-
tion, healthy, unrelated, population-based controls were
included. These controls did not have a history of throm-
bosis and fulfilled the same age criteria as the included
patients.13 Blood samples were obtained at diagnosis. DNA
was extracted from whole blood according to local stan-
dard methods. DNA samples were stored in the Erasmus
MC University Medical Center in Rotterdam at -80°C until
analysis. Presence of CALRmutations was determined with
a PCR fragment analysis examining exon 9. Results of this
PCR were analyzed using Genemapper 4.0, as previously
described.12 MPNs were diagnosed by performing a bone
marrow biopsy (in 49% of patients), JAK2V617F mutation
detection (in 98% of patients), EPO measurements (in 20%
of patients), red cell mass measurement (in 11% of
patients) and/or spontaneous erythroid colony formation
(SECF) testing (in 18% of patients).
DNA samples were available from 77 patients with BCS,
75 patients with PVT and 76 controls. Determination of
CALR mutation was successful in 92% of all samples,
resulting in an inclusion of 70 BCS patients, 71 patients
with PVT and 68 controls in the current analysis. Base-line
characteristics and underlying etiological factors of this
cohort are shown in Table 1. Median age of patients with
BCS and PVT was 43.1 (31.0-53.4) years and 80 (57%)
were female. One or more underlying prothrombotic fac-
tor(s) could be identified in 87% of all patients with BCS
and PVT. MPN was present in 44 patients (31.2%) of
whom 26 (37%) patients with BCS and 18 (26%) patients
with PVT. The median age of patients with MPN was 44.6
(31.1-51.6) years compared to 43.1 (30.2-55.0) years in
patients without MPN (P=0.95). There was also no differ-
ence in male/female distribution between the patients with
and those without MPN (61% and 54% female, respective-
ly; P=0.4). Additional prothrombotic risk factors were diag-
nosed in 32 (73%) of all patients with MPN. Thirty-three of
the 44 patients with MPN had a JAK2V617F mutation
(75%). Of the 11 remaining patients with MPN without
JAK2V617F, 3 (27%) had polycythemia vera (PV) (diagno-
sis based on bone marrow biopsy findings and SECF), 2
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Table 1. Base-line characteristics and etiological factors of the study
cohort.
                                                                     BCS                   PVT
                                                                   (n=70)               (n=71)
Age, years                                                        36.4 (26.4-50.7)  49.8 (41.6-57.2)
Female sex                                                           41 (58.6)              39 (54.9)
ALT (U/L)                                                            65 (32-169)          40 (24-61)
Platelets (*109/L)                                            224 (126-375)     263 (164-403)
White blood cell count (*109/L)                   9.7 (6.7-13.6)      9.5 (7.6-12.8)
Hemoglobin (mmol/L)                                    8.6 (7.5-9.7)        8.2 (7.2-9.3)
Inherited thrombophilia*                                 15 (21.4)              16 (22.5)
Factor V Leiden mutation                            10 (14.3)                4 (5.7)
Prothrombin gene G20210A                           2 (2.9)                 8 (11.4)
Protein C deficiency                                        1 (1.5)                  1 (1.6)
Protein S deficiency                                             0                       3 (4.9)
Antithrombin deficiency                                 2 (3.0)                  2 (3.3)
Acquired thrombophilia*                                  54 (77.1)              52 (73.2)
Myeloproliferative neoplasms                      26 (37.1)              18 (25.7)
Polycythemia vera                                          9 (34.6)                3 (16.7)
Essential thrombocytosis                            5 (19.2)                7 (38.9)
Primary myelofibrosis                                   2 (7.7)                 3 (16.7)
Unclassifiable                                                 6 (23.1)                4 (22.2)
Occult                                                               4 (15.4)                 1 (5.6)
JAK2V617F present                                          19 (27.1)              14 (19.7)
Antiphospholipid antibody syndrome         21 (30.0)              19 (27.5)
Paroxysmal nocturnal hemoglobinuria        9 (12.9)                      0
Hormonal risk factors†                                   16 (39.0)              18 (46.2)
Non-hematologic systemic disorder            8 (11.4)                 2 (2.8)
History of thrombosis                                        14 (20.0)              16 (22.5)
Local risk factor¥                                                  11 (15.7)              19 (26.8)
Single risk factor                                                 24 (34.3)              23 (32.4)
Multiple risk factors                                           39 (55.7)              37 (52.1)
No risk factor                                                        7 (10.0)               11 (15.5)
Results are expressed as median (interquartile range) for continuous variables and
as count (proportion) for categorical variables. *Patients could have more than one
etiological factor simultaneously. †Presence of hormonal risk factor was missing in 29
patients with BCS and 32 patients with PVT. ¥Local risk factors were defined as pres-
ence of an abdominal trauma, abdominal intervention, and/or intra-abdominal infec-
tion, i.e. pancreatitis, liver abcess, cholangitis, cholecystitis, intra-abdominal abcess,
diverticulitis, appendicitis, gastroenteritis, and/or spontaneous bacterial peritonitis
with or without sepsis; BCS: Budd-Chiari syndrome; PVT: portal vein thrombosis;
ALT: alanine aminotransferase. 
patients (18%) had ET, 2 (18%) had PMF, 2 (18%) were
unclassifiable and 2 (18%) had occult MPN, at that time
tested by SECF. The diagnosis of MPN was based on the
above-mentioned criteria and reviewed by a hematologic
expert (FWGL). A CALRmutation was present in only one
MPN patient (2.3% of all patients with MPN). In the 97
BCS and PVT patients without MPN no CALR mutation
was detected. PMF or ET was present in 17 patients with
BCS and PVT in our cohort (39% of all patients with MPN).
Of these 17 patients, 13 (77%) carried a JAK2V617F, one
(6%) had a CALR mutation, and 3 (17%) did not have a
known MPN-associated mutation. 
The patient with a CALR mutation was a 46-year old
female Dutch patient with a cardiomyopathy and PMF
since 1981, resulting in severe splenomegaly requiring
splenectomy in 2003. Pathological examination of the
spleen showed extensive extramedullary hematopoiesis
with signs of multiple non-recent splenic infarctions. Post
operatively, she was diagnosed with PVT including throm-
bosis of the splenic vein and superior mesenteric vein. At
that time, a bone marrow biopsy revealed end-stage PMF.
She did not carry a JAK2V617Fmutation. The CALRmuta-
tion detected in this patient was a type 1 mutation, the
most common encountered CALR mutation, characterized
by a 52-bp deletion in exon 9.11,12 At the moment of diag-
nosis of PVT, platelet count in this patient was increased
(396x109/L), white blood cell count was 6.3x109/L, and
hemoglobin was 5.8 mmol/L. During follow up, she pre-
sented with several episodes of gastrointestinal bleeding
twelve months after diagnosis of PVT, caused by peptic
ulcers under treatment of oral anticoagulants and non-
steroidal anti-inflammatory drugs and angiodysplasia of the
cecum. Fourteen months after diagnosis of PVT, this patient
died of progressive multi-organ failure after presenting with
gastrointestinal bleeding resulting in circulatory collapse.
In summary, in this large European cohort of 141 newly
diagnosed patients with BCS and non-malignant, non-cir-
rhotic PVT, a somatic CALR mutation was present in only
one patient with PVT and in none of the patients with BCS.
This resulted in a prevalence of CALRmutations of 0.7% (1
of 141) in the total cohort, 2.3% (1 of 44) in all patients
with MPN, and 9.1% (1 of 11) in all patients with MPN
without JAK2V617F.  Importantly, no CALR mutations
were detected in patients without MPN or controls. 
Recently, the association between MPN and somatic
mutations in CALR was described for the first time.11,12
CALRmutations were present only in PMF and ET lacking
JAK2V617F and MPL mutations. In patients with PMF or
ET, the prevalence of CALR mutations was reported to be
17%-24%.11,12 In our cohort with only hepatic and/or por-
tal vein thrombosis, the observed prevalence of CALR
mutations in patients with PMF or ET was considerably
lower (6%). This might be attributable to the fact that
patients with a CALRmutation have a lower risk of throm-
bosis compared to patients with a JAK2V617F mutation.
This decreased thrombosis risk may in turn result from the
lower hemoglobin and white blood cell counts observed in
patients with a CALRmutation compared to MPN patients
without a CALR mutation.11,12 This finding is in line with
previous reports that state that CALR-mutant MPN
patients do not develop thrombosis as often as patients car-
rying JAK2V617F, resulting in the lower prevalence of
CALR mutation frequency in our cohort of patients with
BCS and PVT as compared to this prevalence in cohorts of
patients with MPN.14,15 No CALRmutations were observed
in the control group in our study, as was expected based on
the results of the study by Nangalia et al.11 Interestingly,
CALR mutations were also absent in patients with lym-
phoid cancers or solid tumors in that study, suggesting that
CALRmutations might be used as a marker to detect pres-
ence of MPN in BCS and PVT. Two other studies recently
investigated presence of CALR mutations in patients with
BCS and PVT, with comparable results. Turon et al. found a
prevalence of 1.9% CALRmutations in a Spanish cohort of
patients with BCS and PVT and no CALR mutation was
present in a cohort of 144 patients with abdominal vein
thrombosis, also including renal vein, splenic vein and
mesenteric vein thrombosis.16,17 In the current study, we
included 141 consecutive patients with BCS and PVT who
were extensively screened for etiological factors and
prospectively followed in nine European countries. None of
the patients included in the current study was previously
described in the other studies assessing presence of CALR
mutations in BCS and PVT. 
In conclusion, CALR mutations are rare in patients with
BCS and PVT with a prevalence of 0.7% in the total cohort
and 2.3% in patients with MPN. This low prevalence is
probably due to the relatively lower risk of thrombosis in
CALR-mutant patients compared to patients with a
JAK2V617F mutation. Despite this low prevalence, we
believe testing for CALRmutations should be considered in
patients with BCS and PVT who are JAK2V617F negative,
as diagnosing MPN is often difficult in these patients due to
masked blood cell counts because of portal hypertension,
occult gastrointestinal bleeds and/or hypersplenism.
Screening for somatic CALR mutations is an easy to per-
form diagnostic method that could aid in diagnosing MPN
with limited burden for the patient.
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